171 related articles for article (PubMed ID: 38400996)
21. Minimal Physiologically Based Pharmacokinetic-Pharmacodynamic (mPBPK-PD) Model of
Ayyar VS; Song D; Zheng S; Carpenter T; Heald DL
J Pharmacol Exp Ther; 2021 Nov; 379(2):134-146. PubMed ID: 34413198
[TBL] [Abstract][Full Text] [Related]
22. Second-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodies.
Cao Y; Balthasar JP; Jusko WJ
J Pharmacokinet Pharmacodyn; 2013 Oct; 40(5):597-607. PubMed ID: 23996115
[TBL] [Abstract][Full Text] [Related]
23. The interplay of non-specific binding, target-mediated clearance and FcRn interactions on the pharmacokinetics of humanized antibodies.
Datta-Mannan A; Lu J; Witcher DR; Leung D; Tang Y; Wroblewski VJ
MAbs; 2015; 7(6):1084-93. PubMed ID: 26337808
[TBL] [Abstract][Full Text] [Related]
24. Balancing charge in the complementarity-determining regions of humanized mAbs without affecting pI reduces non-specific binding and improves the pharmacokinetics.
Datta-Mannan A; Thangaraju A; Leung D; Tang Y; Witcher DR; Lu J; Wroblewski VJ
MAbs; 2015; 7(3):483-93. PubMed ID: 25695748
[TBL] [Abstract][Full Text] [Related]
25. Utility of Minimal Physiologically Based Pharmacokinetic Models for Assessing Fractional Distribution, Oral Absorption, and Series-Compartment Models of Hepatic Clearance.
Li X; Jusko WJ
Drug Metab Dispos; 2023 Oct; 51(10):1403-1418. PubMed ID: 37460222
[TBL] [Abstract][Full Text] [Related]
26. Toward in vitro-to-in vivo translation of monoclonal antibody pharmacokinetics: Application of a neonatal Fc receptor-mediated transcytosis assay to understand the interplaying clearance mechanisms.
Jaramillo CAC; Belli S; Cascais AC; Dudal S; Edelmann MR; Haak M; Brun ME; Otteneder MB; Ullah M; Funk C; Schuler F; Simon S
MAbs; 2017 Jul; 9(5):781-791. PubMed ID: 28440708
[TBL] [Abstract][Full Text] [Related]
27. Framework selection can influence pharmacokinetics of a humanized therapeutic antibody through differences in molecule charge.
Li B; Tesar D; Boswell CA; Cahaya HS; Wong A; Zhang J; Meng YG; Eigenbrot C; Pantua H; Diao J; Kapadia SB; Deng R; Kelley RF
MAbs; 2014; 6(5):1255-64. PubMed ID: 25517310
[TBL] [Abstract][Full Text] [Related]
28. Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice.
Garg A; Balthasar JP
J Pharmacokinet Pharmacodyn; 2007 Oct; 34(5):687-709. PubMed ID: 17636457
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetic Developability and Disposition Profiles of Bispecific Antibodies: A Case Study with Two Molecules.
Datta-Mannan A; Brown R; Key S; Cain P; Feng Y
Antibodies (Basel); 2021 Dec; 11(1):. PubMed ID: 35076469
[TBL] [Abstract][Full Text] [Related]
30. Prediction of the Pharmacokinetics, Pharmacodynamics, and Efficacy of a Monoclonal Antibody, Using a Physiologically Based Pharmacokinetic FcRn Model.
Chetty M; Li L; Rose R; Machavaram K; Jamei M; Rostami-Hodjegan A; Gardner I
Front Immunol; 2014; 5():670. PubMed ID: 25601866
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of a catenary PBPK model for predicting the in vivo disposition of mAbs engineered for high-affinity binding to FcRn.
Chen Y; Balthasar JP
AAPS J; 2012 Dec; 14(4):850-9. PubMed ID: 22956476
[TBL] [Abstract][Full Text] [Related]
32. A translational platform PBPK model for antibody disposition in the brain.
Chang HY; Wu S; Meno-Tetang G; Shah DK
J Pharmacokinet Pharmacodyn; 2019 Aug; 46(4):319-338. PubMed ID: 31115858
[TBL] [Abstract][Full Text] [Related]
33. Are endosomal trafficking parameters better targets for improving mAb pharmacokinetics than FcRn binding affinity?
Gurbaxani B; Dostalek M; Gardner I
Mol Immunol; 2013 Dec; 56(4):660-74. PubMed ID: 23917469
[TBL] [Abstract][Full Text] [Related]
34. Biologics: an update and challenge of their pharmacokinetics.
Shi S
Curr Drug Metab; 2014 Mar; 15(3):271-90. PubMed ID: 24745789
[TBL] [Abstract][Full Text] [Related]
35. Predicting monoclonal antibody pharmacokinetics following subcutaneous administration via whole-body physiologically-based modeling.
Hu S; D'Argenio DZ
J Pharmacokinet Pharmacodyn; 2020 Oct; 47(5):385-409. PubMed ID: 32500362
[TBL] [Abstract][Full Text] [Related]
36. Interstitial IgG antibody pharmacokinetics assessed by combined in vivo- and physiologically-based pharmacokinetic modelling approaches.
Eigenmann MJ; Karlsen TV; Krippendorff BF; Tenstad O; Fronton L; Otteneder MB; Wiig H
J Physiol; 2017 Dec; 595(24):7311-7330. PubMed ID: 28960303
[TBL] [Abstract][Full Text] [Related]
37. A minimal physiologically based pharmacokinetic model to characterize colon TNF suppression and treatment effects of an anti-TNF monoclonal antibody in a mouse inflammatory bowel disease model.
Zheng S; Niu J; Geist B; Fink D; Xu Z; Zhou H; Wang W
MAbs; 2020; 12(1):1813962. PubMed ID: 32967523
[TBL] [Abstract][Full Text] [Related]
38. Across-Species Scaling of Monoclonal Antibody Pharmacokinetics Using a Minimal PBPK Model.
Zhao J; Cao Y; Jusko WJ
Pharm Res; 2015 Oct; 32(10):3269-81. PubMed ID: 25939552
[TBL] [Abstract][Full Text] [Related]
39. ATLAS mPBPK: A MATLAB-Based Tool for Modeling and Simulation of Minimal Physiologically-Based Pharmacokinetic Models.
Mavroudis PD; Ayyar VS; Jusko WJ
CPT Pharmacometrics Syst Pharmacol; 2019 Aug; 8(8):557-566. PubMed ID: 31154668
[TBL] [Abstract][Full Text] [Related]
40. Impact of altered endogenous IgG on unspecific mAb clearance.
Fuhrmann S; Kloft C; Huisinga W
J Pharmacokinet Pharmacodyn; 2017 Aug; 44(4):351-374. PubMed ID: 28439684
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
